SISAQOL-IMI consortium launches final recommendations

The European Organisation for Research and Treatment of Cancer (EORTC) is pleased to announce the public launch of SISAQOL-IMI final recommendations. SISAQOL-IMI is an international initiative aimed at standardising the analysis of Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL) data in cancer clinical trials. Co-led by EORTC and Boehringer Ingelheim (BI) under the Innovative Medicines Initiative (IMI), this multidisciplinary consortium has brought together 41 stakeholder groups—including researchers, regulators, patient advocates, and industry leaders—to develop consensus-based recommendations that will enhance the use and interpretation of PRO data in cancer research.

On 4 February 2025, SISAQOL-IMI held a public launch event in Ghent, Belgium, where consortium members presented key recommendations and discussed implementation strategies.

“The event also featured a panel discussion with stakeholders reflecting on the anticipated impact of these guidelines in shaping future clinical trials and treatment decisions“, highlighted Dr Madeline Pe, Head of the EORTC Quality of Life Department and co-leader of the SISAQOL-IMI Management and Coordination Work Package.

Importantly also, as the project continues through 2025, efforts will focus on training, dissemination, and ensuring the long-term sustainability of these recommendations, which will be made publicly accessible through an interactive web tool in the course of 2025.

More information about this public launch is available in the related press release on the SISAQOL-IMI website here.

Furthermore, we invite you to explore the executive summary about the public launch to understand the framework, recommendations, and the collaborative efforts that underpin the SISAQOL-IMI initiative. It is available also on the SISAQOL-IMI website, through this link.

This international multidisciplinary project consortium, convened by the European Organisation for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI) aims to establish international standards on how to analyse, interpret and report PRO data gathered in cancer clinical trials. SISAQOL-IMI kicked off at the beginning of January 2021 and will run for four years.
More information about SISAQOL-IMI is available here.

The European Organisation for Research and Treatment of Cancer (EORTC) is a non-governmental, non-profit organisation, which unites clinical cancer research experts, throughout Europe, to define better treatments for cancer patients to prolong survival and improve quality of life. Spanning from translational to large, prospective, multi-centre, phase III clinical trials that evaluate new therapies and treatment strategies as well as patient quality of life, its activities are coordinated from EORTC Headquarters, a unique international clinical research infrastructure, based in Brussels, Belgium.